Exact Sciences (EXAS) Cash Flow Statement

Click line-items for a historical chart and %

Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment
Stock-based compensation	16.77M
Amortization of deferred license fees
Warrant licensing expense
Changes in assets and liabilities:
Prepaid expenses and other current assets	1.7M
Accounts payable	-973K
Accrued expenses	5.45M
Accrued interest	0
Net cash used in operating activities
Cash flows from investing activities:
Purchases of marketable securities	-151.46M
Maturities of marketable securities	142.81M
Purchases of property and equipment	-12.17M
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from Genzyme Collaboration, License and Purchase Agreement
Proceeds from sale of common stock, net of issuance costs	144.25M
Proceeds from exercise of common stock options and stock purchase plan	1.05M
Net cash provided by financing activities
Net (decrease) increase in cash and cash equivalents	22.31M
Cash and cash equivalents, beginning of period	41.14M
Cash and cash equivalents, end of period	63.45M
Supplemental disclosure of non-cash investing and financing activities:
Unrealized gain on available-for-sale investments	410K
Issuance of 27,872 and 15,460 shares of common stock to fund the Company's 401(k) matching contribution for 2010 and 2009, respectively

Entities mentioned with EXAS